Circulating tumour DNA in patients with melanoma receiving targeted therapy

被引：0
|
作者：
Forschner, Andrea [1 ]
机构：
[1] Univ Hosp Tubingen, Dept Dermatol, D-72076 Tubingen, Germany
来源：
LANCET ONCOLOGY | 2021年 / 22卷 / 03期
关键词：
BRAF;
D O I：
10.1016/S1470-2045(20)30758-0
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：291 / 293
页数：3
相关论文
共 50 条
  • [41] Circulating tumour cells in prostate cancer patients receiving salvage radiotherapy
    Lowes, Lori E.
    Lock, Michael
    Rodrigues, George
    D'Souza, David
    Bauman, Glenn
    Ahmad, Belal
    Venkatesan, Varagur
    Allan, Alison L.
    Sexton, Tracy
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2012, 14 (02): : 150 - 156
  • [42] Circulating Tumour DNA Reflects Tumour Burden Independently of Adverse Events Caused by Systemic Therapies for Melanoma
    Ashida, Atsuko
    Sakaizawa, Kaori
    Mikoshiba, Asuka
    Kiniwa, Yukiko
    Okuyama, Ryuhei
    ACTA DERMATO-VENEREOLOGICA, 2019, 99 (12) : 1184 - 1185
  • [43] Circulating tumour cells in prostate cancer patients receiving salvage radiotherapy
    Lori E. Lowes
    Michael Lock
    George Rodrigues
    David D’Souza
    Glenn Bauman
    Belal Ahmad
    Varagur Venkatesan
    Alison L. Allan
    Tracy Sexton
    Clinical and Translational Oncology, 2012, 14 : 150 - 156
  • [44] Circulating Tumour DNA Is a Strong Predictor of Outcomes in Patients Treated with Systemic Therapy for Urothelial Carcinoma
    Laukhtina, Ekaterina
    Hassler, Melanie R.
    Pradere, Benjamin
    Yanagisawa, Takafumi
    Quhal, Fahad
    Rajwa, Pawel
    Motlagh, Reza Sari
    Koenig, Frederik
    Pallauf, Maximilian
    Kawada, Tatsushi
    Mostafaei, Hadi
    D'Andrea, David
    Enikeev, Dmitry
    Shariat, Shahrokh F.
    EUROPEAN UROLOGY FOCUS, 2022, 8 (06): : 1683 - 1686
  • [45] Circulating tumour DNA monitoring and early treatment for relapse: views from patients with early-stage melanoma
    Woof, Victoria G.
    Lee, Rebecca J.
    Lorigan, Paul
    French, David P.
    BRITISH JOURNAL OF CANCER, 2022, 126 (10) : 1450 - 1456
  • [46] Circulating Tumour DNA in Advanced Melanoma Patients Ceasing PD1 Inhibition in the Absence of Disease Progression
    Warburton, Lydia
    Calapre, Leslie
    Pereira, Michelle R.
    Reid, Anna
    Robinson, Cleo
    Amanuel, Benhur
    Ziman, Mel
    Millward, Michael
    Gray, Elin
    CANCERS, 2020, 12 (11) : 1 - 11
  • [47] Circulating tumour DNA monitoring and early treatment for relapse: views from patients with early-stage melanoma
    Victoria G. Woof
    Rebecca J. Lee
    Paul Lorigan
    David P. French
    British Journal of Cancer, 2022, 126 : 1450 - 1456
  • [48] CIRCULATING TUMOUR DNA MARKERS FOR PREDICTION OF SUSTAINED RESPONSE FOLLOWING THE CESSATION OF TARGETED THERAPY AND IMMUNOTHERAPY IN HEPATOCELLULAR CARCINOMA (HCC)
    Li, Qi
    Zhu, Peilin
    Li, Wenli
    Zang, Mengya
    Yuan, Guosheng
    Hu, Xiaoyun
    Chen, Yongru
    HEPATOLOGY, 2024, 80
  • [49] Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study
    Syeda, Mahrukh M.
    Wiggins, Jennifer M.
    Corless, Broderick C.
    Long, Georgina, V
    Flaherty, Keith T.
    Schadendorf, Dirk
    Nathan, Paul D.
    Robert, Caroline
    Ribas, Antoni
    Davies, Michael A.
    Grob, Jean Jacques
    Gasal, Eduard
    Squires, Matthew
    Marker, Mahtab
    Garrett, James
    Brase, Jan C.
    Polsky, David
    LANCET ONCOLOGY, 2021, 22 (03): : 370 - 380
  • [50] Circulating Tumour DNA Is an Independent Prognostic Biomarker for Survival in Metastatic BRAF or NRAS-Mutated Melanoma Patients
    Herbreteau, Guillaume
    Vallee, Audrey
    Knol, Anne-Chantal
    Theoleyre, Sandrine
    Quereux, Gaelle
    Frenard, Cecile
    Varey, Emilie
    Hofman, Paul
    Khammari, Amir
    Dreno, Brigitte
    Denis, Marc G.
    CANCERS, 2020, 12 (07) : 1 - 13
12345